Individualized dosing with axitinib: rationale and practical guidance.
MetadataShow full item record
Axitinib is a potent, selective, vascular endothelial growth factor receptor inhibitor with demonstrated efficacy as second-line treatment for metastatic renal cell carcinoma. Analyses of axitinib drug exposures have demonstrated high interpatient variability in patients receiving the 5 mg twice-daily (b.i.d.) starting dose. Clinical criteria can be used to assess whether individual patients may benefit further from dose modifications, based on their safety and tolerability data. This review provides practical guidance on the 'flexible dosing' method, to help physicians identify who would benefit from dose escalations, dose reductions or continuation with manageable toxicity at the 5 mg b.i.d. dose. This flexible approach allows patients to achieve the best possible outcomes without compromising safety.
Version of record
Carcinoma, Renal Cell
Vascular Endothelial Growth Factor A
Protein Kinase Inhibitors
Dose-Response Relationship, Drug
Molecular Targeted Therapy
License start date
Future oncology (London, England), 2018, 14 (9), pp. 861 - 875